Biotechnology News

Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study CHICAGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc....

REDWOOD CITY, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and...

Press release announcing the findings of a collaborative study with Caregiver Action Network about the caregiver experience.

SAN FRANCISCO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical-stage biotech company developing novel immune modulators to address the unmet need in...

Key milestone marks transition of CHARM into a clinical stage company Initial data anticipated in 2027 LONDON – 7 October 2026 -- CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage...

WINNIPEG, Manitoba, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and...

MENLO PARK, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are...

Matchpoint Therapeutics Announces $150 Million Series B Financing

Consistent Use of New Approach Methodologies (NAMs) to Potentially Accelerate BiTAC® Oncology Pipeline and Significantly Reduce Animal Testing Needs.

Updated preclinical data and clinical trial-in-progress poster from the Harmony-HHT Phase 1/2 trial support the ongoing development of ATV-1601, an investigational oral allosteric inhibitor that...